Edition:
United Kingdom

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

2.92USD
23 Apr 2018
Change (% chg)

$-0.24 (-7.59%)
Prev Close
$3.16
Open
$3.15
Day's High
$3.15
Day's Low
$2.92
Volume
34,768
Avg. Vol
61,122
52-wk High
$5.55
52-wk Low
$1.75

Select another date:

Mon, Mar 19 2018

BRIEF-OncoMed Announces Appointment Of John Lewicki As CEO

* ONCOMED ANNOUNCES APPOINTMENT OF JOHN LEWICKI, PHD, AS PRESIDENT, CHIEF EXECUTIVE OFFICER AND A MEMBER OF THE BOARD OF DIRECTORS

BRIEF-Oncomed Pharmaceuticals Reports Q4 Earnings Per Share $0.25

* ONCOMED PHARMACEUTICALS - CURRENT CASH IS ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 OF 2019

BRIEF-OncoMed Q4 Earnings Per Share $0.25

* ONCOMED ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Oncomed Says Chief Executive Officer Paul Hastings Has Resigned

* ONCOMED ANNOUNCES CHAIRMAN, PRESIDENT AND CHIEF EXECUTIVE OFFICER PAUL J. HASTINGS HAS RESIGNED

BRIEF-OncoMed Estimates 2018 Operating Cash Burn To Be Less Than $55 Mln

* ONCOMED PROVIDES 2018 OUTLOOK AND 2017 YEAR-END CASH BALANCE AND ANNOUNCES AN UPDATE ON THE ROSMANTUZUMAB PROGRAM

BRIEF-Perceptive Advisors reports 6.5 pct passive stake in Oncomed Pharmaceuticals

* PERCEPTIVE ADVISORS LLC REPORTS A 6.5 PCT PASSIVE STAKE IN ONCOMED PHARMACEUTICALS INC AS OF NOV 6 - SEC FILING Source text: [http://bit.ly/2nzZrC0] Further company coverage:

BRIEF-Oncomed says CEO Paul Hastings to Resume Chairman of Board Responsibilities

* ONCOMED - ‍CHAIRMAN, PRESIDENT, CEO PAUL HASTINGS WILL RESUME CHAIRMAN OF BOARD RESPONSIBILITIES, EFFECTIVE DEC. 4, 2017​

BRIEF-Oncomed posts Q3 loss per share $0.28

* Oncomed announces third quarter 2017 financial results and operational highlights

Select another date: